Q1 2025 EPS Estimates for Haemonetics Co. Lifted by Zacks Research (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Research analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Haemonetics in a note issued to investors on Friday, April 19th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $0.95 per share for the quarter, up from their previous forecast of $0.94. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.05 EPS, FY2025 earnings at $4.16 EPS, Q1 2026 earnings at $1.23 EPS, Q2 2026 earnings at $1.17 EPS and FY2026 earnings at $4.85 EPS.

A number of other equities research analysts also recently issued reports on HAE. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. Finally, StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Stock Up 2.9 %

Haemonetics stock opened at $83.61 on Monday. Haemonetics has a one year low of $70.74 and a one year high of $95.26. The stock has a fifty day moving average of $79.15 and a 200 day moving average of $82.65. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The stock has a market cap of $4.25 billion, a PE ratio of 33.99, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.85 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. State of Michigan Retirement System increased its holdings in Haemonetics by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock worth $1,065,000 after acquiring an additional 300 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Haemonetics by 132.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after purchasing an additional 286,897 shares during the period. AlphaMark Advisors LLC purchased a new stake in shares of Haemonetics in the first quarter worth $304,000. Cardinal Capital Management raised its position in shares of Haemonetics by 26.5% during the 1st quarter. Cardinal Capital Management now owns 14,283 shares of the medical instruments supplier’s stock valued at $1,219,000 after purchasing an additional 2,994 shares during the period. Finally, Dynamic Advisor Solutions LLC raised its position in shares of Haemonetics by 2.1% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock valued at $1,562,000 after purchasing an additional 374 shares during the period. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.